This Market Spotlight report covers the Glioblastoma (GBM) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, probability of success, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Despite Truvada’s and Descovy’s commercial success, PrEP remains underutilized due to poor awareness and lack of/limited reimbursement in some European countries, though uptake is increasing due to recent favorable reimbursement decisions in Germany, Spain, England, Wales, and Northern Ireland, as well as due to Gilead’s marketing efforts. The US has the highest rate of uptake (estimated at 22% of at-risk individuals in 2020) and generates the majority of global PrEP revenues.
The HIV treatment market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand through to 2025, driven primarily by increases in disease prevalence and continued uptake of Gilead’s Biktarvy and ViiV Healthcare’s portfolio of two-drug regimens. However, a plethora of products undergoing patent expiry across the forecast period will tip the market into decline from 2026.
This report provides an overview of diabetes, automated insulin pump systems, and a comprehensive market and competitive analysis.
Asthma and COPD, the two most prevalent respiratory diseases, affect nearly 600 million people worldwide, with annual mortality rates exceeding 3 million for COPD and 400,000 for asthma. COVID-19 has infected more than 60 million people worldwide, resulting in 1.5 million deaths. This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the positive airway pressure (PAP)-based noninvasive ventilation (NIV) and airway management products market, including CPAP and BiPAP devices as well as heat/moisture exchangers (HMEs), humidifiers, and nebulizers (including large- and small-volume nebulizers and nebulizer compressors).
This medical market and technology report provides a comprehensive discussion of the global market for extremities replacement implants. Market forecasts and competitive analyses are provided for the shoulder, elbow, ankle, and small joint arthroplasty devices markets. Geographic segments covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of October 2021, there have been 245,373,039 confirmed cases of COVID-19, and 4,979,421 deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus.
COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 12 March 2021, there have been 117,799,584 confirmed cases of COVID-19, and 2,615,018 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans.
This medical market and technology report provides a comprehensive discussion of the global market for knee replacement implants. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for melanoma. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include lifileucel, seviprotimut-L, Lenvima, and TAVO.
A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Diagnostic testing and unmet needs are also discussed. Key pipeline assets highlighted include Keytruda, Tecentriq, ipatasertib, DCVAC/PCa, capivasertib, Lutetium 177Lu-PSMA-617, and Cabometyx.
This interview with a US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for colorectal cancer. Disease stratifications by staging and expression profile of the primary tumor, as well as unmet needs, are also discussed. Key therapies highlighted include Keytruda, Braftovi, Opdivo, Avastin (and bevacizumab biosimilars), Herceptin (and trastuzumab biosimilars), Lonsurf, and Erbitux.
The Annual European Society for Medical Oncology (ESMO) 2020 Congress was held virtually from September 19 to September 21, 2020 due to the COVID-19 pandemic.
This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems.
The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!